2012, Number S1
<< Back Next >>
Rev Mex Anest 2012; 35 (S1)
Anesthesia for chemotherapy in isolation limb perfusion in the oncologic patient
Cabrera-Rojas JJ, Martínez-Said H
Language: Spanish
References: 10
Page: 69-73
PDF size: 231.23 Kb.
Text Extraction
No abstract
REFERENCES
Martínez SH, Herrera GA, et al. Perfusión aislada de extremidad. Una alternativa a la amputación en tumores avanzados por melanoma, sarcomas y otros tumores irresecables de las extremidades. Médica Sur México 2002;9.
Duarte C, Melo M, Venegas M. Perfusión aislada de extremidades. Rev Colomb Cancerol 2008;12:213-218.
Douglas T. Where are we going with regional therapy for melanoma? Annals of Surgery Oncology 2004;11:455-457.
Calvo E, et al. Perfusión de extremidad aislada en sarcomas de partes blandas irresecables: Un nuevo estándar. Rev Ortop Traumatol 2004;48:57-64.
Eggimann P, et al. Systemic and hemodynamic effects of recombinant TNF–a in limb isolation perfusion. Chest 1995:107.
Wieberdink K, Benckhuyjsen C, Braat RP, van Slooten EA, Oldhios GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-10.
Byrne DS, McKay AJ, Blackie R, Mackie RM. A comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity. Eur J Cancer 1996;32A:2082-2087.
Calvo E et al. Perfusión de extremidad aislada en Oncología. Rev Oncol 2003;5:128-38.
Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
Hill S, Fawcett WJ, Sheldon, J et al. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993;80:995-7.
Full text